Cognetivity Neurosciences
AI-powered cognitive testing platform for early dementia detection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | CAD4.5m | Post IPO Equity |
| Total Funding | 000k | ||
| CAD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1050 %) | (3287 %) | (9273 %) | - | - | - | (13825 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1011 %) | (3295 %) | (9235 %) | - | - | - | (16386 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 139 % | 181 % | 1613 % | - | - | - | 1325 % |
Source: Company filings or news article
Related Content
Cognetivity Neurosciences is a medical technology company that has developed an AI-powered platform for early detection of cognitive impairment. Founded in April 2013 by Dr. Sina Habibi and Dr. Seyed-Mahdi Khaligh-Razavi, who met during their PhD studies at Cambridge University, the company was born from a side project inspired by Dr. Habibi's grandmother's experience with dementia. Dr. Khaligh-Razavi has a background in computer science, machine learning, and neuroscience from Cambridge and MIT, while Dr. Habibi has a PhD in Engineering from Cambridge and experience in entrepreneurship and high-tech consultancy.
The company's core product is the CognICA™ Integrated Cognitive Assessment, a five-minute, tablet-based test that uses artificial intelligence and machine learning to analyze a user's reaction to images of animals. This method tests large areas of the brain to detect the earliest signs of cognitive dysfunction, such as in dementia and Alzheimer's disease, often before traditional symptoms become apparent. The platform is designed to be highly sensitive, free of cultural or educational bias, and avoids the learning effect seen in traditional pen-and-paper tests. Cognetivity's business model involves licensing its CognICA™ platform to healthcare providers, including hospitals and primary care clinics, for use in medical, commercial, and consumer environments. Commercial agreements have been established with healthcare networks in the US, UK, Europe, and the Middle East.
Cognetivity has achieved significant regulatory milestones, including a CE mark for European markets and FDA 510(k) clearance in the United States in October 2021, allowing for commercial distribution. The company has also engaged in numerous funding rounds to support its commercial expansion. However, the company has faced recent challenges, including a cease trade order in June 2024 due to delays in filing annual financial statements. The Canadian Securities Exchange (CSE) announced the delisting of the company's common shares effective May 29, 2025.
Keywords: cognitive assessment, artificial intelligence, medical technology, dementia detection, brain health, neuroscience, machine learning, CognICA, Alzheimer's disease, digital health, cognitive screening, FDA clearance, CE mark, neurodegenerative diseases, cognitive dysfunction, healthcare technology, clinical assessment, early diagnosis, remote monitoring, mental health